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Abstract
Chondrogenesis is a process involving stem-cell differentiation
through the coordinated effects of growth/differentiation factors
and extracellular matrix (ECM) components. Recently,
mesenchymal stem cells (MSCs) were found within the
cartilage, which constitutes a specific niche composed of ECM
proteins with unique features. Therefore, we hypothesized that
the induction of MSC differentiation towards chondrocytes
might be induced and/or influenced by molecules from the
microenvironment. Using microarray analysis, we previously
identified genes that are regulated during MSC differentiation
towards chondrocytes. In this study, we wanted to precisely
assess the differential expression of genes associated with the
microenvironment using a large-scale real-time PCR assay,
according to the simultaneous detection of up to 384 mRNAs in
one sample. Chondrogenesis of bone-marrow-derived human
MSCs was induced by culture in micropellet for various periods
of time. Total RNA was extracted and submitted to quantitative
RT-PCR. We identified molecules already known to be involved
in attachment and cell migration, including syndecans,
glypicans, gelsolin, decorin, fibronectin, and type II, IX and XI
collagens. Importantly, we detected the expression of molecules
that were not previously associated with MSCs or
chondrocytes, namely metalloproteases (MMP-7 and MMP-28),
molecules of the connective tissue growth factor (CTGF);
cef10/cyr61 and nov (CCN) family (CCN3 and CCN4),
chemokines and their receptors chemokine CXC motif ligand
(CXCL1), Fms-related tyrosine kinase 3 ligand (FlT3L),
chemokine CC motif receptor (CCR3 and CCR4), molecules
with A Disintegrin And Metalloproteinase domain (ADAM8,
ADAM9, ADAM19, ADAM23, A Disintegrin And
Metalloproteinase with thrombospondin type 1 motif ADAMTS-
4 and ADAMTS-5), cadherins (4 and 13) and integrins (α4, α7
and β5). Our data suggest that crosstalk between ECM
components of the microenvironment and MSCs within the
cartilage is responsible for the differentiation of MSCs into
chondrocytes.Page 1 of 12
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α-MEM = α-minimum essential medium; ADAM = A Disintegrin And Metalloproteinase molecule; ADAMTS = A Disintegrin And Metalloproteinase 
with thrombospondin type 1 motif; ALCAM = Activated leukocyte cell adhesion molecule; b-FGF = basic fibroblast growth factor; BSA = bovine 
serum albumin; CAM = cell-adhesion molecule; CCL = chemokine CC motif ligand; CCN = CTGF; cef10/cyr61 and nov; CCR = chemokine CC 
motif receptor; COMP = cartilage oligomeric matrix protein; Ct = threshold cycle; CTGF = connective tissue growth factor; CXCL = chemokine CXC 
motif ligand; CXCR = chemokine CXC motif receptor; CYR = cysteine-rich angiogenic inducer; DMEM = Dulbecco's modified Eagle's medium; ECM 
= extracellular matrix; EDTA = ethylene diamine tetracetic acid; FACS = fluorescence-activated cell sorter; FBS = fetal bovine serum; FlT3L = Fms-
related tyrosine kinase 3 ligand; GAPDH = glyceraldehyde-3-phosphate dehydrogenase; hBMP = human bone morphogenetic protein; Hg = Hedge-
hog; ICAM = intercellular cell adhesion molecule; ITS = insulin-transferrin-selenic acid; LEF = lymphoid enhancer binding factor; mAb = monoclonal 
antibody; MCAM = melanoma cell adhesion molecules; MMP = metalloprotease; MSC = mesenchymal stem cell; NOV = nephroblastoma overex-
pressed; NRCAM = neuronal cell adhesion molecule; OA = osteoarthritis; PBS = phosphate-buffered saline; PG = proteoglycan; PTH = parathyroid 
hormone; RA = rheumatoid arthritis; RT-PCR = reverse transcriptase polymerase chain reaction; SEM = standard error of the mean; TGF = trans-
forming growth factor; TLDA = Taqman® low-density assay; VCAM = vascular cell adhesion molecule; WISP = Wnt1-inducible signalling pathway 
protein; Wnt = wingless.
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In articular cartilage, chondrocytes were thought to represent
a unique cell type, but with a phenotype differing in the super-
ficial, mid, deep and calcified zones [1]. However, mesenchy-
mal stem cells (MSCs) have been recently identified in
articular cartilage and are thought to represent up to 3.5% of
the constituent cells [2]. The number of MSCs might even
increase in the cartilage of patients with osteoarthritis (OA),
compared with healthy cartilage, raising the possibility that
these progenitor cells would be involved in the pathogenesis
of arthritis, differentiating abnormally in response to the inflam-
matory milieu of the joint and signals from the extracellular
matrix (ECM). The role of MSCs present in the cartilage is
unknown.
Adult MSCs are pluripotent progenitor/stem cells; their prog-
eny includes chondrocytes, tendon cells, haematopoiesis-sup-
port stromal cells, adipocytes and osteoblasts [3,4]. MSCs,
similar to other stem cells, have an essential role in the regen-
eration/maintenance of the adult tissues submitted to physio-
logical modelling/turnover or following injury. The fundamental
property shared by all stem cells is their ability to balance the
cell-fate decision between self-renewal and differentiation.
The microenvironment regulates the maintenance of the stem-
cell pool and commitment towards specific lineages through
intrinsic and extrinsic factors, creating niches. For this regula-
tion, adhesion of stem cells to the ECM is crucial. Cells and
ECM adhesion molecules that enable cell communication are
the prerequisite for tissue formation and maintenance.
The mechanisms that regulate chondrogenic differentiation
include both autonomous (stem-cell intrinsic) and non-cell-
autonomous (microenvironmental) components. Chondrogen-
esis is driven by a coordinated effect of hormones (such as
parathyroid hormone (PTH)), morphogens (such as Hedgehog
(Hg) or wingless (Wnt) proteins) and cytokines (such as mem-
bers of the bone morphogenetic protein (BMP) and transform-
ing growth factor (TGF)-β family) through their respective
receptors [5]. However, many other factors drive the differen-
tiation of MSCs towards cartilage, including ECM molecules,
such as proteoglycans (PGs; syndecans and glypicans) or
fibulins [6,7]. Members of the connective tissue growth factor
(CTGF); cef10/cyr61 and nov (CCN) family, in addition to mol-
ecules with A Disintegrin And Metalloprotease domain
(ADAM), and integrins have also been shown to have a crucial
role in chondrogenesis [8]. These ECM molecules might inter-
act with growth factors, chemokines or members of the Wnt
family, or their receptors, to modulate their signalling [9]. Stud-
ies have demonstrated that normal chondrocytes adhere to
various amounts of type I and IV collagens, thrombospondin,
vitronectin, fibronectin, laminin and fibrinogen through the
RGD (Arg-Gly-Asp) sequence and integrin-mediated interac-
tions [10]. Indeed, there is a vast range of cellular responses
to cell–matrix interactions, depending on the integrin recep-
tors expressed by the cell and the composition of the sur-
rounding ECM.
Because the cartilaginous microenvironment is composed of
ECM proteins, closely associated to stem cells and chondro-
cytes, we hypothesized that the molecules of the ECM might
create a niche specifying chondrocytic differentiation of MSCs
in situ and, therefore, that the corresponding receptors would
be differentially expressed in the undifferentiated MSCs com-
pared with fully differentiated chondrocytes. We previously
established a genomic profile of human MSCs before and
after their differentiation into chondrocytes, using the cDNA
chip technology (F Djouad, D Noël, unpublished data). How-
ever, this technology is currently limited by the relative lack of
reproducibility, absence of quantitative results and amounts of
required RNA. To elucidate the microenvironmental signals
involved in the chondrogenic differentiation of MSCs, we
designed a large-scale Taqman® low-density array (TLDA)
(Applied Biosystems, Courtaboeuf, France) using real-time
RT-PCR, enabling the simultaneous quantitative analysis of
384 mRNA transcripts. The data have been assembled into a
biological process-oriented database, serving as a model for
the cartilage MSC niche.
Materials and methods
Cell culture
Human MSC cultures were established from bone-marrow
aspirates of two healthy donors (aged 36 and 40 years) after
informed consent. Mononuclear cells were plated at a density
of 5 × 104 cells/cm2 in α-minimum essential medium (α-MEM),
supplemented with 10% fetal bovine serum (FBS; Perbio Sci-
ence France SAS, Brebières, France), 1 ng/ml basic fibroblast
growth factor (b-FGF), 100 U/ml penicillin and 100 μg/ml
streptomycin. When cultures reached near confluence, cells
were detached with 0.05% trypsin and 0.53 mM ethylene
diamine tetracetic acid (EDTA) and subsequently re-plated at
a density of 1,000 cells/cm2. MSCs were used at passage 3
to 4 and shown to be positive for CD44, CD73, CD90 and
CD105 and negative for CD14, CD34 and CD45, as previ-
ously described [11].
In vitro chondrogenic differentiation
Chondrogenic differentiation of MSCs was induced by 21-day
culture in micropellet [12]. Briefly, MSCs (2.5 × 105 cells)
were pelleted by centrifugation in 15 ml conical tubes and cul-
tured in BMP-2-conditioned chondrogenic medium. Condi-
tioned medium consisted of the supernatant of C9 cells
cultured for 48 hours in DMEM supplemented with 0.1 μM
dexamethasone, 0.17 mM ascorbic acid and 1% insulin-trans-
ferrin-selenic acid (ITS) supplement (Sigma, l'Isle d'Abeau,
France) [12]. C9 cells derived from the C3H10T1/2 murine
MSC line expressing human BMP-2 (1,231 ng/24 h/106 cells)
under control of a TetOff promoter [13]. As a control, condi-
tioned media from C3H10T1/2 cells were unable to induce
any cell differentiation, at least for the chondrogenic- and oste-Page 2 of 12
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(data not shown).
RNA preparation
At day 0, MSCs cultured in monolayer were harvested by treat-
ment with 0.05% trypsin and 0.53 mM EDTA, washed with
PBS and pelleted at 300 g for 5 minutes at 4°C. At day 2, 7
and 21 of chondrogenesis, micropellets (15 to 20) were
recovered, washed in PBS and mechanically dissociated.
Total RNA (3 μg) was extracted using the RNeasy (Quiagen
S.A., Courtaboeuf, France) kit, according to the recommenda-
tions of the manufacturer.
TaqMan® real-time RT-PCR
TLDAs (microfluidic cards; Applied Biosystems) were used in
a two-step RT-PCR process [14]. First-strand cDNA was syn-
thesized from 3 μg total RNA using the high-capacity cDNA
archive kit (Applied Biosystems). Quantitative PCR reactions
were then carried out using the microfluidic cards and the ABI
PRISM 7900HT Sequence Detection System (Applied Bio-
systems). The 384 wells of each card were preloaded with
predesigned fluorogenic TaqMan® probes and primers. cDNA
(800 ng) combined with 1X TaqMan® Universal Master Mix
(Applied Biosystems) were loaded into each well (2 ng/well).
The microfluidic cards were thermal cycled at 50°C for 2 min-
utes and 94.5°C for 10 minutes, followed by 40 cycles at
97°C for 30 seconds and 59.7°C for 1 minute. Data were col-
lected using instrument spectral compensations by the SDS
2.1 software (Applied Biosystems) and analysed using the
threshold-cycle (Ct) relative-quantification method. The con-
tent of the cDNA samples was normalized by subtracting the
number of copies of the endogenous glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) reference gene from the Ct of
the target gene (ΔCt = Ct of target gene - Ct of GAPDH). The
results for the complete list of the tested transcripts are
expressed as the mean of 2-ΔCt ± the standard error of the
mean (SEM) at the different time points and shown as supple-
mentary data (Additional file 1).
Fluorescence-activated cell sorter analysis
MSCs were plated in tissue-culture flasks in chondrogenic
medium, with or without 10 ng/ml hBMP-2 (R&D Systems,
Lille, France), and cultured for 48 hours. Cells were harvested
by treatment with 0.05% trypsin and 0.53 mM EDTA. After
chondrogenic induction, micropellets were dissociated by
treatment with 2 mg/ml collagenase type IA-S (Sigma). After a
wash with PBS, isolated cells were suspended in PBS con-
taining 0.1% BSA and 0.01% sodium azide and incubated on
ice with primary mAbs for 30 minutes. The mouse mAbs used
were specific for human CD29 (integrin β1, cloned March 4),
CD49a (integrin α1), CD49d (integrin α4), CD49e (integrin
α5), CD49f (integrin α6), CD106 (vascular cell adhesion mol-
ecule; VCAM1), CD146 (melanoma cell adhesion molecule;
MCAM), chemokine CC motif receptor (CCR)3, CCR4, chem-
okine CXC motif receptor (CXCR)4 or isotypic controls (R&D
Systems). Flow cytometry was performed on a fluorescence-
activated cell sorter (FACS) scan and data were analysed with
the Cellquest software (BD Pharmingen, Le Pont de Claix,
France). Data are expressed as the percentage of cells posi-
tive for the marker analysed ± SEM.
Results and discussion
Chondrogenesis is tightly regulated by growth and differentia-
tion factors, involving prominently the FGF, TGF-β, BMP, Wnt
and Hg pathways [14]. This process is controlled by cellular
interactions with the surrounding matrix and other environmen-
tal factors that initiate or suppress cellular signalling in a spa-
tiotemporal manner, including the level of oxygen, mechanical
tension and cellular contact with the components of the carti-
laginous matrix, which are essential for the maintenance of the
adult tissue homeostasis [5]. Using the microarray technology,
we previously investigated the gene-expression profile of
human bone-marrow-derived MSCs for 21 days, before and
after their differentiation into chondrocytes, using the micro-
pellet culture system and hBMP-2 as the inducing factor (F
Djouad, D Noël, unpublished data). Of the genes upregulated
during chondrogenesis, numerous genes corresponding to
constituents of the ECM or membrane-bound proteins were
identified. We thus investigated whether such genes might be
modulated during the time-course of chondrogenesis and take
part in the differentiation process. We took advantage of using
the TLDA, which enables precise and simultaneous quantifica-
tion of the expression of 384 different mRNAs in a single
experiment. We designed a card with primer sets correspond-
ing to genes belonging to the stem cell, osteoblast, chondro-
cyte, adipocyte and myocyte signatures. Of the 384 mRNAs
tested, 16% were not expressed at any time and 21% are pre-
sented below (Additional file 1).
Time-course expression of chondrocyte-specific markers 
during the differentiation of mesenchymal stem cells
First, we confirmed that MSCs underwent chondrogenesis by
determining the expression of the mRNA specific for aggrecan
and type II collagen at day 21 by quantitative RT-PCR (data
not shown). Second, we performed the TLDA on RNA
extracted at different time points during chondrogenesis. In
cartilage, there are several different types of collagens and
PGs. PGs can be divided into the following types: ECM-asso-
ciated components, such as aggrecan, the major chondroitin
sulphate PG, in addition to small leucin-rich PGs, such as
decorin and biglycan; and cell-surface components, the glypi-
cans and syndecans. Of the cell-surface components, synde-
can-4 is more abundant than syndecan-2, whereas syndecan-
3 is briefly expressed during the early stages of chondrogene-
sis [15]. Through their heparin and chondroitin sulfate PGs,
both glypicans and syndecans interact with growth factors,
such as FGF, Hg and Wnt, and their receptors, affecting their
biological effects by modulation of their signalling. Although
their role has been controversial, the binding of ligands to the
heparan sulfate PGs might protect the ligand from the recep-Page 3 of 12
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[16] and participate in the regulation of the cellular phenotype
within the cartilage. In this study, the expression kinetic of var-
ious ECM transcripts shows that, at the early stage of the dif-
ferentiation process (day 2 and 7), most of the transcripts
were downregulated, whereas they were upregulated by more
than threefold on day 21. Of these transcripts, only type II col-
lagen and glypican 3 were absent in MSCs, whereas all of the
other transcripts were expressed at various levels on day 0
(Figure 1a,b). The data confirmed the upregulation of PGs and
collagens known to be overexpressed and/or specific to the
articular cartilage, such as aggrecan, biglycan, glypicans,
mimecan, syndecans, decorin, and type II, III, X and XI colla-
gens (Figure 1a,b). The cartilage also contains numerous pro-
teins that are neither collagens nor PGs and have a structural
role in the matrix, such as cartilage oligomeric matrix protein
(COMP), dermatopontin and fibronectin, or are part of the
cytoskeleton, such as filamin [17]. Other proteins, such as
osteonectin and osteopontin, are involved in the mineralization
of cartilage. The corresponding mRNAs were increased on
day 21, except for filamin (Figure 1a,b).
Gelsolin is involved in the cytoskeletal organization and
induced by integrin signalling. The expression of gelsolin and
mimecan was recently described in OA chondrocytes, in addi-
tion to the upregulation of gelsolin in hypertrophic
chondrocytes [18,19], but, to our knowledge, the expression
of gelsolin in MSCs has not been previously reported. Of the
Figure 1
Time-course expression of major components of the chondrocyte-associated extracellular matrix (ECM). The gene-expression profile of mesenchy-
mal stem cells (MSCs; n = 2) was analysed by real-time PCR during their differentiation towards chondrocytes in micropellets. (a) and (b) Change 
in the expression levels of various proteoglycans (PGs), collagens and proteins of the ECM. Genes were arbitrarily distributed. COMP, cartilage oli-
gomeric matrix protein; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; PCR, polymerase chain reaction.Page 4 of 12
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corin and necdin are of interest. The expression of corin in
MSCs and its upregulation in chondrocytes was unexpected
because this protein has been associated with hypertrophic
cardiomyocyte and myocardium failure [20]. Necdin is an
inductor of myogenesis [21] and inhibitor of brown adipogen-
esis [22]. However, the increased expression of these two pro-
teins during chondrogenesis (1,370- and 6.5-fold,
respectively) might reflect an important role during MSC
differentiation.
In summary, the upregulation of these various molecules
known to be associated with the chondrocyte phenotype con-
firms that chondrogenic differentiation occurs under our exper-
imental conditions and validates the use of the quantitative
PCR assay for the detection of various ECM or membrane-
associated components and the analysis of their potential role
in chondrogenesis.
Modulation of the expression of secreted proteins 
during chondrogenic differentiation
The members of the CCN family are secreted, cysteine-rich,
regulatory proteins that interact with growth factors and have
important functions in cell proliferation and differentiation in
bone and cartilage, in particular [23]. The family includes
CCN1/cysteine-rich, angiogenic inducer (CYR)61, CCN2/
CTGF, CCN3/nephroblastoma overexpressed (NOV) and the
Wnt1-inducible signalling pathway (WISP) proteins (WISP 1
to 3 (CCN4 to 6)). The transcriptional profile of MSCs
revealed the expression of CCN1, CCN2, CCN3 and CCN5
(data not shown); these results were validated by quantitative
PCR for CCN3, CCN4 and CCN5 (Figure 2a). Our data partly
confirm a recent study reporting the mRNA expression of
CCN1, CCN2, CCN5 and CCN6 in MSCs, with a decrease in
CCN1 and CCN6 expression during the chondrogenic differ-
entiation of MSCs, suggesting that these proteins might be
important regulators in the maintenance of the stem-cell phe-
notype [24]. However, we also observed the expression of
CCN3 and CCN4 in MSCs by quantitative PCR and the
mRNA levels increased twofold to threefold after chondrogen-
esis (Figure 2a). To our knowledge, the possibility that CCN3
and CCN4 are expressed in MSCs and expression of CCN3,
CCN4 and CCN5 is upregulated after chondrogenesis has
not been previously raised. In the study of Schutze and co-
workers, the use of semiquantitative RT-PCR instead of real-
time PCR might explain the lower degree of sensitivity of the
detection [24]. The role of these CCN members in chondro-
genesis remains to be elucidated. However, evidence that
CCN5 can inhibit the proliferation, invasiveness and motility of
vascular smooth muscle cells as a growth-arrest-specific gene
has been provided [25]. This suggests that CCN5 might mod-
ulate the proliferation of MSCs during the course of the differ-
entiation process.
The timely degradation of the ECM is an important feature of
development, morphogenesis and remodelling and mainly
mediated by matrix MMPs or matrixins. MMPs are grouped into
collagenases, gelatinases, stromelysins, matrilysins, mem-
brane-type MMPs, mainly according to their substrate prefer-
ence [26]. MMP-1, MMP-2, MMP-3, MMP-7, MMP-9, MMP-12
and MMP-28 are expressed in cartilage [27-29] and, with the
exception of MMP-9, we also observed increased levels of
expression of the corresponding mRNA after chondrogenic
differentiation of MSCs. However, little is known about the
expression of these MMPs in MSCs, although the presence of
MMP-2 and MMP-3 and absence of MMP-1 and MMP-9 have
been reported [30]. We confirmed these data and also
showed the expression of MMP-28 and absence of MMP-7 in
MSCs and the upregulation during chondrogenesis of all the
MMPs tested, except for MMP-9 (Figure 2b). Recently, MMP-
9 was shown to be involved in regulating pericellular proteoly-
sis for correct endochondral bone formation during the in vitro
differentiation pathway and in vivo cartilage repair process
[31]. Indeed, the absence of MMP-9 in both MSCs and
Figure 2
Change in the expression levels of proteins secreted by the chondro-cyte-associat d extracellular matrix (ECM)
cyte-associated extracellular matrix (ECM). The gene-expression profile 
of mesenchymal stem cells (MSCs; n = 2) was analysed by real-time 
PCR during their differentiation towards chondrocytes in micropellets. 
(a) Time-course expression of the members of the CCN family of 
genes. (b) Time-course expression of various MMPs. CCN, connective 
tissue growth factor (CTGF); cef10/cyr61 and nov; GAPDH, glyceral-
dehyde-3-phosphate dehydrogenase; MMP, metalloprotease; PCR, 
polymerase chain reaction.Page 5 of 12
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undergoing terminal differentiation in our culture conditions, as
suggested by low (1.75-fold) upregulation of type X collagen
in MSCs after differentiation.
Modulation of the expression of chemokines and their 
receptors during chondrogenic differentiation
Chemokines are small, heparin-binding proteins that direct the
movement of circulating leukocytes to sites of inflammation or
injury [32]. Different chemokines have also been demon-
strated to influence bone-cell functions, bone-tissue remodel-
ling and stem-cell engraftment [33]. A number of chemokines
(chemokine CC motif ligand (CCL)2, CCL4, CCL5, CCL20,
CXCL12, CX3CL1, CXCL8, CXCL13 and CXCL16) and
chemokine receptors (CCR1, CCR7, CCR9, CXCR4,
CXCR5, CXCR6 and CX3CR1) have been detected in MSCs
[34,35]. Here, we confirm the expression of these chemokines
by MSCs, when tested and report CXCL1 and Fms-related
tyrosine kinase 3 ligand (Flt3L) expression (Figure 3a). One
study has already reported the expression of Flt3L in placenta-
derived MSCs [36], but, to our knowledge, this is the first
report of CXCL1 expression in bone marrow-derived MSCs, at
least at the mRNA level. By contrast, most of the chemokine
receptors previously described in MSCs were not found,
except CX3CR1 (Figure 3b). This discrepancy is probably
owing to the conditions of cell isolation and/or in vitro culture
or the fact that only a minority of cells express these receptors
[35]. CX3CR1 is the only receptor that showed total inhibition
of its mRNA during chondrogenesis (from day 2). Interestingly,
we detected the expression of CCR3 at the mRNA level, in
addition to CCR3, CCR4 and CXCR4 at the protein level (Fig-
ure 4a). To our knowledge, the expression of CCR3 was not
previously reported in MSCs. Moreover, the levels of all of
these receptors increased during chondrogenesis.
Chondrocytes are known to express CCR1, CCR2, CCR3,
CCR5, CCR6, CXCR1, CXCR2, CXCR3, CXCR4 and
CXCR5 [37,38]. Only CCR1, CCR3 and CXCR4 mRNAs
were detected in MSC-derived chondrocytes, and we report
the expression of CCR4 in these cells (Figure 3b). Interest-
ingly, a huge increase (122- to 2,152-fold) in the levels of
these mRNAs was observed after cell differentiation. Their
respective cytokines (CCL3, CCL5 and CXCL12) were also
expressed in MSC-derived chondrocytes (Figure 3a).
Whereas most of the chemokines and their receptors were
concomitantly modulated, an inverse correlation between the
expression of the CX3CR1 and CXCR4 receptors and the
expression of their ligands (CX3CL1 and CXCL12, respec-
tively) was observed during the course of chondrogenesis.
This inversely proportional expression of CXCL12/CXCR4
was recently observed in MSCs cultured on a hyaluronic acid-
based scaffold [39]. The authors suggest that the scaffold
probably helps to mobilize the internalized receptor, increasing
its functional expression and improving engraftment. Accord-
ing to our data, it might also be assumed that the expression
of some receptors, notably CXCR4, might reflect progression
through chondrogenesis and/or be implicated in the differenti-
ation process. Because interactions between chemokine
receptors, syndecans and PGs are known to facilitate the
binding of chemokines to their ligands [40], the modulation of
the expression of these receptors is probably a crucial event in
the migration, attachment or differentiation of MSCs in the
specific environment of the joint. In this environment, both
immune cells and synoviocytes are other potential sources of
chemokines that might influence the migration and homing of
MSCs to the cartilage.
Modulation of the expression of cell-surface markers 
during chondrogenic differentiation
Expression of members of A Disintegrin And 
Metalloprotease family
ADAM proteins contain a disintegrin and MMP domain, which
has the dual function of cleavage/release of cell-surface pro-
teins and remodelling of the ECM [41]. These proteins interact
with various partners, such as integrins, syndecans and ECM
proteins and are involved in developmental events, including
myogenesis, neurogenesis, adipogenesis and morphogene-
sis. In this study, we report the expression of ADAM8, ADAM9,
ADAM19, ADAM23, A Disintegrin-like And Metalloproteinase
with thrombospondin type 1 motif (ADAMTS)-4 and ADAM-
TS5 in MSCs and their upregulation at the late stage of chon-
drogenesis, in particular ADAMTS-4 and ADAMTS-5 (Figure
5a). Moreover, we show the presence of ADAM19 and
ADAM23, which have not been previously associated with
chondrocytes. The involvement of ADAMTS-4 and ADAMTS-
5 has already been reported in aggrecan breakdown during
endochondral ossification [42]. Expression of the ADAMTS-5
is also increased by Wnt/β-catenin signalling, which was
shown to regulate chondrocyte phenotype, maturation and
function in a developmentally regulated manner and to be
crucial for growth-plate organization and endochondral ossifi-
cation [43]. These molecules are also implicated in diseases,
such as OA and rheumatoid arthritis (RA), in which the
ADAMTS-5, expressed in joint tissue, was shown to be the
major aggrecanase involved in cartilage destruction [44,45].
Moreover, to our knowledge, this is the first report of the
expression of several ADAM proteins, at least at the mRNA
level, in MSCs and their upregulation during chondrogenic dif-
ferentiation. The upregulation of the two ADAMTS molecules
at the late stage of chondrogenesis might be related to hyper-
trophic terminal differentiation. Although the role of the ADAM
molecules during the chondrogenic process remains to be elu-
cidated, they might interact with integrins, PGs and ECM pro-
teins to build a microenvironment favouring the appearance of
the chondrocytic phenotype.
Expression of adhesion molecules
Some adhesion molecules, such as cadherins or CAMs, have
important functions in development and tissue morphogene-
sis, in particular cadherin 11 and N-cadherin, which have aPage 6 of 12
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sponding mRNAs, in addition to mRNAs for cadherins 4 and
13, were expressed in MSCs, and their level of expression was
increased on day 21 (Figure 5b). The appearance of tran-
scripts for cadherin 11, as early as day 2, confirms its role dur-
ing early chondrogenesis and in differentiation. The expression
of cadherin 4 and 13 in MSCs has not been previously
reported. Because cadherin 4 has been associated with neu-
ral retina differentiation [47,48], its role in cartilage develop-
ment needs further investigation.
Of the adhesion molecules, we present evidence for the
expression of all of the CAM molecules tested in MSCs and an
increase in their mRNA levels during chondrogenesis, by more
than 30-fold for MCAM and neuronal cell adhesion molecule
(NRCAM) (Figure 5b). A subset of MSCs is known to express
activated leukocyte cell adhesion molecule (ALCAM)
(CD166), MCAM (CD146), VCAM1 (CD106) and
intercellular cell adhesion molecule (ICAM)2 (CD102) [34],
whereas chondrocytes express only ALCAM and VCAM1
[49]. However, NRCAM has not been previously described in
MSCs and chondrocytes, and ICAM2 has not been previously
Figure 3
Time-course expression of chemokines and their receptors during chondrogenic differentiation of mesenchymal stem cells (MSCs). The gene-
expression profile of MSCs (n = 2) was analysed by real-time PCR during their differentiation towards chondrocytes in micropellets. (a) Change in 
the expression levels of various chemokines. (b) Change in the expression levels of various chemokine receptors. CCL, chemokine CC motif ligand; 
CCR, chemokine CC motif receptor; CXCL, chemokine CXC motif ligand; CXCR, chemokine CXC motif receptor; FlT3L, Fms-related tyrosine 
kinase 3 ligand; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; PCR, polymerase chain reaction.Page 7 of 12
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opment of the cerebellar system [50] and is a target gene of
the β-catenin/lymphoid enhancer binding factor (LEF)-1
pathway in melanoma and colon cancer [51]. Because the
Wnt/β-catenin pathway is active in chondrogenesis, it might
be speculated that β-catenin induces the upregulation of
NRCAM in the micropellet culture. Whether its expression
might be involved in cartilage formation, as seen in the cere-
bellar system, remains to be demonstrated.
Expression of members of the integrin family
The integrin family of CAMs are transmembrane glycoproteins,
composed of α and β subunits and their combination deter-
mines ligand specificity. The patterns of integrin expression
determine the adhesive properties of cells by modulating their
interactions with specific ECM proteins, suggesting they
might be involved in differentiation and migration [52]. MSCs
exhibit the expression of integrins α1, α2, α3, α5, α6, αv, β1,
β3 and β4 [53]. Here, we confirm these data and show the
expression of integrins α4, α7 and β5, whereas integrin β7 is
not expressed (Figure 5c). Expression of integrins α1, α4, α5
and β1 was confirmed by FACS analysis (Figure 4b,c). With
the exception of integrin α4, which was previously shown to be
absent using FACS analysis, integrins α7 and β5 have not
been demonstrated to be expressed by MSCs. The lack of
detection of the integrin α4 protein by other authors might be
attributed to the weak expression of this marker or conditions
used for cell isolation/culture.
In chondrocytes, we detected the expression of all of the
integrins tested. This confirms previous data reporting expres-
sion of integrins α1, α2, α3, α5, α6, α10, αv, β1, β3 and β5
[52]. Integrin α5β1 is the most prominently expressed integrin
in chondrocytes and integrin α10β1 is the dominant collagen-
binding integrin during mouse cartilage development [52,54].
Although the mRNA levels of the various integrins slightly
increase during chondrogenic differentiation (Figure 5c), the
protein levels tend to decrease with time (Figure 4b). These
data suggest that the subunits of integrins are regulated dur-
ing the differentiation process. This has already been shown
for integrin β1, in addition to a switch from α1 to α3 integrins
during chondrogenesis [52]. However, no information is avail-
able on the role of integrins α4, α7, β5 and β7 during chondro-
genesis. Integrins containing the α4 or α7 subunit bind to
RGD-containing components, namely fibronectin and vit-
ronectin or laminin, respectively. Because these components
are localized in the cartilaginous ECM, they are probably
involved in cellular responses, depending on their interaction
with the various integrin receptors expressed by the MSCs.
Role of bone morphogenetic protein 2 in the modulation 
of adhesion molecules at the surface of mesenchymal 
stem cells
Because chondrogenic differentiation was performed by cul-
ture in micropellets in the presence of BMP-2, we investigated
whether the modulation of expression of some molecules
might be induced by BMP-2 and not by the differentiation
process. To this aim, we checked the expression of several
integrins and two adhesion proteins at the surface of MSC that
had been cultured for 2 days in monolayer in proliferative
medium with/without BMP-2. We observed the low, but signif-
icant, expression of the integrins α1, α4 and α6 and VCAM1
at the protein level, whereas the integrins α5 and β1 and
MCAM were highly expressed (Figure 4c). However, no signif-
icant increase in integrin expression was measured after stim-
ulation with BMP-2 for 48 hours. These results suggest that
BMP-2 does not modulate the expression levels of adhesion
molecules, at least for the proteins and time point tested.
Conclusion
In summary, our study shows that the TLDA could be a useful
tool for monitoring the modulation of mRNA profiles during dif-
ferentiation processes. This assay relies on the use of minor
quantities of material (2 ng of total RNA/gene) and quantifica-
tion of up to 384 genes in the same sample in one experiment.
We found that most of the ECM or membrane-associated mol-
Figure 4
Modulation of the expression of cell-surface proteins on mesenchymal stem cells (MSCs)
stem cells (MSCs). (a) and (b) Change in the protein levels of various 
surface markers during chondrogenic differentiation of MSCs (n = 2) in 
the micropellet. (c) Change in the protein levels at the surface of MSCs 
cultured in monolayer with human BMP-2 for 48 hours. CCR, chemok-
ine CC motif receptor; CXCR, chemokine CXC motif receptor; MCAM, 
melanoma cell adhesion molecule; SEM, standard error of the mean; 
VCAM, vascular cell adhesion molecule.Page 8 of 12
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Expression levels of ADAM and adhesion molecules during chondrogenic differentiation of mesenchymal stem cells (MSCs). The gene-expression 
profile of mesenchymal stem cells (MSCs; n = 2) was analysed by real-time PCR during their differentiation towards chondrocytes in micropellets. 
Change in the expression levels of various ADAM family members (a), several cadherins and CAMs (b) and a number of integrins (c). ADAM, A Dis-
integrin And Metalloproteinase molecule; ALCAM, activated leukocyte CAM; CAM, cell-adhesion molecule; GAPDH, glyceraldehyde-3-phosphate 
dehydrogenase; ICAM, intercellular CAM; MCAM, melanoma CAM; NRCAM, neuronal CAM; PCR, polymerase chain reaction; ADAMTS, A Disin-
tegrin And Metalloproteinase with thrombospondin type 1 motif; VCAM, vascular cell adhesion molecule.Page 9 of 12
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that are involved in attachment and cell migration, such as
PGs, collagens, MMPs, CCN proteins, chemokines and their
receptors, ADAM proteins, cadherins and integrins, were
reproducibly detected. Indeed, although the study has been
performed on few samples, these results are encouraging pre-
liminary data. We suggest that these components are involved
in crosstalk between the ECM and the MSCs, which might
constitute the direct microenvironment of MSCs within the
cartilage tissue, and the chondrogenic process (Figure 6).
Moreover, a number of components that were not previously
reported to be expressed in MSCs and/or chondrocytes have
been identified. Although their expression will have to be con-
firmed on a statistically relevant number of donors at the pro-
tein level, this sets up the basis for a more accurate work on
their role in chondrogenesis.
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